BioNTech struck a partnership with DualityBio Monday morning to delve into next-generation antibody-drug conjugate (ADC) therapeutics in cancer and autoimmune diseases. The deal gives BioNTech access ...

Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...

(Reuters) - Germany's BioNTech said on Monday that it signed a deal with Chinese biotech company DualityBio to co-develop and commercialize two cancer antibody drug candidates. DualityBio will receive ...

BioNTech has turned to dealmaking yet again to diversify its cancer drug pipeline, paying $170 million to begin an alliance with Duality Biologics. The deal includes a clinical-stage drug candidate ...

BioNTech will expand its pipeline into antibody-drug conjugates (ADCs) and deepen its presence in oncology through an up-to-$1.67 billion collaboration with Duality Biologics (DualityBio), the ...

A year and a half after debuting on the world stage with its Pfizer-partnered COVID vaccine, BioNTech wants to prove it’s not a one-hit wonder, touting early data of a pancreatic cancer vaccine combo ...

He has conquered Covid for the time being, and now the CEO of BioNTech says he wants to turn his attention back to his first interest: cancer. Dr. Ugur Sahin is trying out the same mRNA technology ...

The emergency phase of the COVID-19 pandemic is over but the story of BioNTech, which emerged as one of the leading vaccine makers during the crisis, is still ongoing. To that end, National Geographic ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...